Quantity: Box of 20 tests
Description: High Quality Professional Rapid Antigen Test Kits. Only $9.90 per test
- TGA Approved
- Results in just 15 minutes.
- Convenient and easy to use
- Simple step by step instructions
The Medomics COVID-19 Antigen Test is a lateral flow immunochromatographic assay for the qualitative detection of the SARS-CoV-2 nucleocapsid protein antigen in nasopharyngeal and nasal swab specimens directly collected from individuals who are suspected of COVID-19 by their healthcare provider.
The Medomics COVID-19 Antigen Test is intended for use by medical and healthcare professionals.
The test offers high sensitivity and specificity to aid in the early diagnosis of COVID-19.
The Test Includes:
Instructions for use
Individually sealed test cassettes
Sampling tubes containing individual lysis buffer
Sterile swabs sealed in a paper-plastic pouch
The Medomic COVID-19 Antigen Test is a lateral ﬂow immunochromato-graphic assay intended for the qualitative detection of the nucleocap-sid protein antigen from SARS-CoV-2 in nasopharyngeal or anterior nasal swab specimens directly collected from individuals who are either suspected of COVID-19 by their healthcare provider within the ﬁrst ﬁve days of symptom onset. This test is intended for use at the Point of Care (POC).
Results are for the identiﬁcation of the SARS-CoV-2 nucleocapsid protein antigen. The antigen is generally detectable in nasopharynge-al or anterior nasal swab specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but the clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out a bacterial infection or co-infection with other viruses. The agent detected may not be the deﬁnite cause of disease. Laboratories are required to report all positive results to the appropriate public health authorities.
Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19, and conﬁrmed with a molecular assay, if necessary, for patient management.
|Unit Of Measure||ea|
We Also Recommend
Others Also Bought
Now from $16.95
More From This Category